BIOGEN IDEC INC. - CORPORATE HEADQUARTERS

In the beginning, Biogen assembled a team of biologists, each doing breakthrough science in small, separate labs. The emphasis was on important science; two of the co-founders, Phillip Sharp and Walter Gilbert, went on to win the Nobel Prize. Biogen was one of the first companies to develop recombinant proteins using genetic technology. This pioneering work ultimately led to the development of AVONEX®, an interferon beta-1a used to treat multiple sclerosis.

Today, Biogen Idec is a $4 billion Fortune 500 company, serving patients around the world. We are proud to have been an important member of the biotechnology industry since its infancy and continue to pursue new ways to create new standards of care in therapeutic areas with high unmet medical needs.

A commitment to research is fundamental to our mission at Biogen Idec; to create new standards of care for unmet medical needs, we must continually develop more effective ways to approach research.

With our stated mission to create new standards of care for unmet medical needs, Biogen Idec is focused on five therapeutic areas: Neurology, Immunology, Oncology, Cardiopulmonary and Hemophilia. These are areas in which we have both proven expertise and products in our pipeline that we believe can lead to first-in-class or best-in-class molecules. Within each area, we have selected targets based on both biology and the pathophysiology of disease.

Our Support Specialists can help patients and their caregivers understand their insurance coverage and any out-of-pocket costs. Additionally, Biogen Idec provides a variety of financial assistance programs for people taking one of our medications that are tailored to meet the needs of a range of situations. Specifically, we have programs for uninsured people, people who are privately insured, and people insured through public programs, such as Medicare.

At Biogen Idec, we are focused on our patients, and how we can help them manage their illnesses.